N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

NCT ID: NCT01265563 Phase: PHASE2 Status: COMPLETED Enrollment: 108 Completion: 2016-12

Conditions

Diabetic Nephropathy, Proteinuria, Oxidative Stress

Interventions

N-acetylcysteine placebo and silibin placebo, N-acetylcysteine active and silibin placebo, N-acetylcysteine placebo and silibin active, N-acetylcysteine active and silibin active, N-acetylcysteine active + high-dose silibin active

Summary

The study is done to find out whether the combined use of the nutritional supplements N-acetylcysteine and Siliphos (milk thistle extract) corrects the shedding of urine protein and oxidative damage (damage to cells and organs often compared to fast aging) in patients with Type 2 Diabetes Mellitus (T2DM) and diabetic kidney disease.

Primary Outcome

Change From Baseline in Urinary Albumin Excretion

Source

ClinicalTrials.gov